

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 NOV 21 CAS patent coverage to include exemplified prophetic  
substances identified in English-, French-, German-,  
and Japanese-language basic patents from 2004-present  
NEWS 3 NOV 26 MARPAT enhanced with FSORT command  
NEWS 4 NOV 26 CHEMSAFE now available on STN Easy  
NEWS 5 NOV 26 Two new SET commands increase convenience of STN  
searching  
NEWS 6 DEC 01 ChemPort single article sales feature unavailable  
NEWS 7 DEC 12 GBFULL now offers single source for full-text  
coverage of complete UK patent families  
NEWS 8 DEC 17 Fifty-one pharmaceutical ingredients added to PS  
NEWS 9 JAN 06 The retention policy for unread STNmail messages  
will change in 2009 for STN-Columbus and STN-Tokyo  
NEWS 10 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent  
Classification Data  
NEWS 11 FEB 02 Simultaneous left and right truncation (SLART) added  
for CERAB, COMPUAB, ELCOM, and SOLIDSTATE  
NEWS 12 FEB 02 GENBANK enhanced with SET PLURALS and SET SPELLING  
NEWS 13 FEB 06 Patent sequence location (PSL) data added to USGENE  
NEWS 14 FEB 10 COMPENDEX reloaded and enhanced  
NEWS 15 FEB 11 WTEXTILES reloaded and enhanced  
  
NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:29:48 ON 16 FEB 2009

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 17:30:01 ON 16 FEB 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 FEB 2009 HIGHEST RN 1106670-14-7  
DICTIONARY FILE UPDATES: 15 FEB 2009 HIGHEST RN 1106670-14-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.



Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10574982\Struc 1.str



```

chain nodes :
10 11 12 13 17 18 19 20
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
7-17 8-10 10-11 11-12 11-13 18-19 18-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
5-7 6-9 7-8 7-17 8-9 8-10 11-12 11-13 18-19 18-20
exact bonds :
10-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

```

G1:Cb,Cy,Hy

Match level :

10574982.trn


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
11:CLASS 12:CLASS 13:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:Atom

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1 Cb,Cy,Hy

Structure attributes must be viewed using STN Express query preparation.

=> l1

SAMPLE SEARCH INITIATED 17:30:37 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 108 TO ITERATE

100.0% PROCESSED 108 ITERATIONS

4 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 1537 TO 2783

PROJECTED ANSWERS: 4 TO 200

L2 4 SEA SSS SAM L1

=> l1 full

FULL SEARCH INITIATED 17:30:40 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 2536 TO ITERATE

100.0% PROCESSED 2536 ITERATIONS

103 ANSWERS

SEARCH TIME: 00.00.01

L3 103 SEA SSS FUL L1

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	185.88	186.10

FILE 'CAPLUS' ENTERED AT 17:30:43 ON 16 FEB 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Feb 2009 VOL 150 ISS 8  
FILE LAST UPDATED: 15 Feb 2009 (20090215/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>



This file contains CAS Registry Numbers for easy and accurate substance identification.

=> 13  
L4 1 L3

=> d ibib abs

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2005:346984 CAPLUS  
DOCUMENT NUMBER: 142:411223  
TITLE: Preparation of fused bicyclic compounds, in particular 1-oxo-1,3-dihydroisoindole derivatives, as fibrinogen receptor antagonists and their use for treating thrombotic and other diseases  
INVENTOR(S): Lal, Bansij; Gangopadhyay, Ashok Kumar; Rao, Vadlamudi V. S. V.; Gupte, Ravindra Dattatraya; Gole, Gopal Vishnu; Kulkarni-Almeida, Asha; Krishnan, Sridevi; Panicker, Radha Bhaskar; Pinto De Souza, Eleanor  
PATENT ASSIGNEE(S): Nicholas Piramal India Limited, India  
SOURCE: PCT Int. Appl., 179 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005035495	A2	20050421	WO 2004-IB51922	20040930
WO 2005035495	A3	20050707		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2003MU01054	A	20060616	IN 2003-MU1054	20031008
EP 1677783	A2	20060712	EP 2004-787579	20040930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK US 20070021489 A1 20070125 US 2006-574982 20060407				
PRIORITY APPLN. INFO.:			IN 2003-MU1054 A 20031008	
			WO 2004-IB51922 W 20040930	
OTHER SOURCE(S):			CASREACT 142:411223; MARPAT 142:411223	
GI				



AB The invention is related to novel fused bicyclic compds. I [wherein A = aryl, 5- or 6-membered heteroaryl; RA = NO2, CONH2 and derivs., carbamimidoyl, etc.; m = 1-3; when m = 2-3 the RA groups are independent of each other; RB = H, halo, CN, NO2, NH2 and derivs., partially or fully

fluorinated alkyl etc.; RC = H, alkyl, :O, NH and derivs., etc.; U = (CH<sub>2</sub>)<sub>n</sub>(CRDRE)(C:RF)RG; n = 0-5, RD, RE = independently H, (un)substituted alk(en/yn)yl, aryl, heterocyclyl, etc.; RF = ;O, S, :N(OH) and derivs., etc.; RG = (un)substituted hetero/aryl, partially or fully saturated heterocyclyl, their stereoisomers, tautomers, pharmaceutically acceptable salts, solvates and prodrugs. The invention is also related to the preparation of compds. I and their use, alone or in combination with other therapeutic agents. I are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex. For example, II was prepared via amination of 2-Bromomethyl-4-cyanobenzoic acid Et ester (preparation given) with [4-(2-Aminoacetyl)phenoxy]acetic acid Me ester, in situ cyclization in DMF/DCM at room temperature overnight and reaction with NH<sub>2</sub>OH•HCl. In human platelet-rich plasma, selected I inhibited platelet aggregation induced by ADP with an IC<sub>50</sub> < 0.093 μM. I inhibited collagenase-induced thrombocytopenia in guinea pigs. I and their pharmaceutical compns. are useful for the inhibition of platelet aggregation, and for the treatment of thrombotic diseases and other diseases.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> file reg
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                               ENTRY      SESSION
FULL ESTIMATED COST          4.00      190.10

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  SINCE FILE      TOTAL
                                               ENTRY      SESSION
CA SUBSCRIBER PRICE          -0.82      -0.82
```

FILE 'REGISTRY' ENTERED AT 17:32:06 ON 16 FEB 2009  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 FEB 2009 HIGHEST RN 1106670-14-7  
 DICTIONARY FILE UPDATES: 15 FEB 2009 HIGHEST RN 1106670-14-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdnc/properties.html>

=>  
 Uploading C:\Program Files\Stnexp\Queries\10574982\Struc 2.str

10574982.trn



```

chain nodes :
10 11 12 13 17
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
7-17 8-10 10-11 11-12 11-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
5-7 6-9 7-8 7-17 8-9 8-10 11-12 11-13
exact bonds :
10-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

```

G1:Cb,Cy,Hy

G2:O,S

Match level :

10574982.trn




1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
11:CLASS 12:CLASS 13:CLASS 17:CLASS

L5 STRUCTURE UPLOADED

=> d

L5 HAS NO ANSWERS

L5 STR



G1 Cb,Cy,Hy

G2 O,S

Structure attributes must be viewed using STN Express query preparation.

=> 15

SAMPLE SEARCH INITIATED 17:32:22 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 7243 TO ITERATE

27.6% PROCESSED 2000 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*



PROJECTED ITERATIONS: 139758 TO 149962

PROJECTED ANSWERS: 4312 TO 6262

L6 50 SEA SSS SAM L5

=>

Uploading C:\Program Files\Stnexp\Queries\10574982\Struc 3.str



```

chain nodes :
10 11 12 13 17 18 19 20
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
7-17 8-10 10-11 11-12 11-13 18-19 18-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
5-7 6-9 7-8 7-17 8-9 8-10 11-12 11-13 18-19 18-20
exact bonds :
10-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

```

G1:Cb,Cy,Hy

G2:O,S,N

10574982.trn

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
11:CLASS 12:CLASS 13:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:Atom

L7 STRUCTURE UPLOADED

=> d

L7 HAS NO ANSWERS

L7 STR



G1 Cb,Cy,Hy

G2 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> 17

SAMPLE SEARCH INITIATED 17:34:10 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 508 TO ITERATE

100.0% PROCESSED 508 ITERATIONS

4 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 8808 TO 11512

PROJECTED ANSWERS: 4 TO 200

L8 4 SEA SSS SAM L7

=> 17 full

FULL SEARCH INITIATED 17:34:16 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 10739 TO ITERATE

100.0% PROCESSED 10739 ITERATIONS

104 ANSWERS

10574982.trn

SEARCH TIME: 00.00.01

L9 104 SEA \$\$\$ FUL L7

=> file caplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
187.32	377.42

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-0.82

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 17:34:20 ON 16 FEB 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Feb 2009 VOL 150 ISS 8  
FILE LAST UPDATED: 15 Feb 2009 (20090215/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> l9  
L10 1 L9

=&gt; d ibib abs hitstr 1

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:346984 CAPLUS

DOCUMENT NUMBER: 142:411223



TITLE: Preparation of fused bicyclic compounds, in particular 1-oxo-1,3-dihydroisoindole derivatives, as fibrinogen receptor antagonists and their use for treating thrombotic and other diseases

INVENTOR(S): Lal, Bansi; Gangopadhyay, Ashok Kumar; Rao, Vadlamudi V. S. V.; Gupte, Ravindra Dattatraya; Gole, Gopal Vishnu; Kulkarni-Almeida, Asha; Krishnan, Sridevi;

10574982.trn

PATENT ASSIGNEE(S): Panicker, Radha Bhaskar; Pinto De Souza, Eleanor  
 SOURCE: Nicholas Piramal India Limited, India  
 PCT Int. Appl., 179 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005035495	A2	20050421	WO 2004-IB51922	20040930
WO 2005035495	A3	20050707		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
IN 2003MU01054	A	20060616	IN 2003-MU1054	20031008
EP 1677783	A2	20060712	EP 2004-787579	20040930
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
US 20070021489	A1	20070125	US 2006-574982	20060407
PRIORITY APPLN. INFO.:			IN 2003-MU1054	A 20031008
			WO 2004-IB51922	W 20040930
OTHER SOURCE(S):	CASREACT 142:411223; MARPAT 142:411223			
GI				



AB The invention is related to novel fused bicyclic compds. I [wherein A = aryl, 5- or 6-membered heteroaryl; RA = NO<sub>2</sub>, CONH<sub>2</sub> and derivs., carbamimidoyl, etc.; m = 1-3; when m = 2-3 the RA groups are independent of each other; RB = H, halo, CN, NO<sub>2</sub>, NH<sub>2</sub> and derivs., partially or fully fluorinated alkyl etc.; RC = H, alkyl, :O, NH and derivs., etc.; U = (CH<sub>2</sub>)<sub>n</sub>(CRDRE)(C:RF)RG; n = 0-5, RD, RE = independently H, (un)substituted alk(en/yn)yl, aryl, heterocyclyl, etc.; RF = :O, S, :N(OH) and derivs., etc.; RG = (un)substituted hetero/aryl, partially or fully saturated heterocyclyl], their stereoisomers, tautomers, pharmaceutically acceptable salts, solvates and prodrugs. The invention is also related to the preparation of compds. I and their use, alone or in combination with other therapeutic agents. I are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex. For example, II was prepared via amination of 2-Bromomethyl-4-cyanobenzoic acid Et ester (preparation given) with [4-(2-Aminoacetyl)phenoxy]acetic acid Me ester, in situ cyclization in DMF/DCM at room temperature overnight and reaction with NH<sub>2</sub>OH•HCl. In human platelet-rich plasma, selected I inhibited platelet aggregation induced by ADP with an IC<sub>50</sub> < 0.093 μM. I inhibited collagenase-induced thrombocytopenia in guinea pigs. I and their pharmaceutical compns. are useful for the inhibition of platelet aggregation, and for the treatment of thrombotic diseases and other diseases.

IT 850396-86-0P, [4-[2-(5-Carbamimidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]acetic acid methyl ester 850396-87-1P, [4-[2-(5-Carbamimidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]acetic acid methyl ester acetate 850396-93-9P, [4-[2-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid methyl ester 850396-94-0P, [4-[2-(5-Carbamimidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]acetic acid ethyl ester 850396-98-4P, [4-[2-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid ethyl ester 850396-99-5P, [4-[2-(5-Carbamimidoyl-1-oxo-1,3-dihydroisoindol-2-

yl)acetyl]phenoxy]acetic acid isopropyl ester 850397-04-5P,  
 [4-[2-[5-[(Imino)(methoxycarbonylamino)methyl]-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]acetic acid isopropyl ester 850397-05-6P,  
 [4-[2-[5-[(Imino)(isobutoxycarbonylamino)methyl]-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]acetic acid isopropyl ester 850397-06-7P,  
 [4-[2-[5-[(Benzyloxycarbonylamino)(imino)methyl]-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]acetic acid isopropyl ester 850397-07-8P,  
 [4-[2-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]acetic acid isopropyl ester 850397-08-9P,  
 [4-[2-(5-Carbamimidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]acetic acid isobutyl ester hydroiodide  
 850397-14-7P, [4-[2-[5-[(Imino)(methoxycarbonylamino)methyl]-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]acetic acid isobutyl ester  
 850397-15-8P, [4-[2-[5-[(Imino)(isobutoxycarbonylamino)methyl]-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]acetic acid isobutyl ester  
 850397-16-9P, [4-[2-[5-[(Benzyloxycarbonylamino)(imino)methyl]-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]acetic acid isobutyl ester  
 850397-17-0P, [4-[2-[5-[(Imino)(methylsulfonyl)amino)methyl]-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]acetic acid isobutyl ester  
 850397-18-1P, [4-[2-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]acetic acid isobutyl ester  
 850397-19-2P, [4-[2-(5-Carbamimidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]acetic acid benzyl ester 850397-20-5P,  
 [4-[2-(5-Carbamimidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]acetic acid benzyl ester acetate 850397-27-2P,  
 [4-[2-(5-Carbamimidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]acetic acid hydrochloride 850397-30-7P,  
 [4-[2-[5-[(Imino)(methoxycarbonylamino)methyl]-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]acetic acid benzyl ester 850397-31-8P,  
 [4-[2-[5-[(Imino)(isobutoxycarbonylamino)methyl]-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]acetic acid benzyl ester 850397-32-9P,  
 [4-[2-(5-Carbamimidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]-2-[(ethoxycarbonyl)methoxy]phenoxy]acetic acid ethyl ester  
 850397-33-0P, [4-[2-(5-Carbamimidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]-2-[(ethoxycarbonyl)methoxy]phenoxy]acetic acid ethyl ester  
 acetate 850397-41-0P, [2-[(Ethoxycarbonyl)methoxy]-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]acetic acid ethyl ester 850397-42-1P,  
 [2-[(Ethoxycarbonyl)methoxy]-4-[2-[5-[(imino)(3-methylbutyrylamino)methyl]-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]acetic acid ethyl ester  
 850397-43-2P, [2-[(Ethoxycarbonyl)methoxy]-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl)-1-(hydroxyimino)ethyl]phenoxy]acetic acid ethyl ester 850397-44-3P,  
 [4-[2-(5-Carbamimidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]-2-[(isobutoxycarbonyl)methoxy]phenoxy]acetic acid isobutyl ester hydroiodide  
 850397-50-1P, 2-[4-[2-(5-Carbamimidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]-N,N-diethylacetamide 850397-51-2P,  
 2-[4-[2-(5-Carbamimidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]-N,N-diethylacetamide acetate 850397-56-7P,  
 4-[2-[4-[2-(5-Carbamimidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]acetoxypiperidine-1-carboxylic acid benzyl ester  
 850397-62-5P, 4-[(Benzyloxycarbonyl)amino]-2-[4-[2-(5-carbamimidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]butyric acid ethyl ester  
 850397-63-6P, 4-[(Benzyloxycarbonyl)amino]-2-[4-[2-(5-carbamimidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]butyric acid ethyl ester acetate  
 850397-71-6P, 4-[(Benzyloxycarbonyl)amino]-2-[4-[2-[5-(N-

hydroxycarbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]butyric acid ethyl ester 850397-72-7P,  
 [[4-[2-[5-(N-Hydroxycarbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenyl]sulfonyl]acetic acid methyl ester 850397-78-3P,  
 [4-[2-(5-Carbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]-2-chlorophenoxy]acetic acid ethyl ester 850397-79-4P,  
 [4-[2-(5-Carbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]-2-chlorophenoxy]acetic acid ethyl ester acetate 850397-85-2P,  
 [2-Chloro-4-[2-[5-[(imino)(isobutoxycarbonylamino)methyl]-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid ethyl ester 850397-86-3P,  
 [2-Chloro-4-[2-[5-(N-hydroxycarbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid ethyl ester 850397-87-4P,  
 [4-[2-(5-Carbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]-2-(ethylsulfonyl)phenoxy]acetic acid ethyl ester 850397-88-5P,  
 [4-[2-(5-Carbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]-2-(ethylsulfonyl)phenoxy]acetic acid ethyl ester acetate 850397-96-5P,  
 [2-Ethylsulfonyl-4-[2-[5-(N-hydroxycarbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid ethyl ester 850397-97-6P,  
 [4-[2-(5-Carbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]-2-ethylsulfonylphenoxy]acetic acid ethyl ester 850397-98-7P,  
 [4-[2-(5-Carbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]-2-ethylsulfonylphenoxy]acetic acid ethyl ester acetate 850398-04-8P,  
 [2-Ethylsulfonyl-4-[2-[5-(N-hydroxycarbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid ethyl ester 850398-05-9P,  
 [2,6-Bis(ethylsulfonyl)-4-[2-[5-(N-hydroxycarbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid ethyl ester 850398-14-0P,  
 [2-Acetyl-4-[2-[5-(N-hydroxycarbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid ethyl ester 850398-22-0P,  
 [2-[(Ethoxycarbonyl)methyl](methylsulfonyl)amino]-4-[2-[5-[(imino)(isobutoxycarbonylamino)methyl]-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid ethyl ester 850398-32-2P,  
 [2-[(Ethoxycarbonyl)methyl](methylsulfonyl)amino]-4-[2-[5-(N-hydroxycarbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid ethyl ester 850398-33-3P,  
 [4-[2-(5-Carbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]-3-hydroxyphenoxy]acetic acid ethyl ester 850398-34-4P,  
 [4-[2-(5-Carbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]-3-hydroxyphenoxy]acetic acid ethyl ester acetate 850398-41-3P,  
 [3-Hydroxy-4-[2-[5-(N-hydroxycarbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid ethyl ester 850398-42-4P,  
 [3-Hydroxy-4-[2-[5-(N-hydroxycarbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid benzyl ester 850398-50-4P,  
 [4-[2-(5-Carbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]-3-hydroxyphenoxy]acetic acid 850398-51-5P,  
 [4-[2-(5-Carbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]-3-hydroxyphenoxy]acetic acid trifluoroacetate 850398-52-6P,  
 [4-[2-[5-(N-Hydroxycarbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]-3-methoxyphenoxy]acetic acid ethyl ester 850398-57-1P,  
 [4-[2-[5-(N-Hydroxycarbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]-3-propoxyphenoxy]acetic acid ethyl ester 850398-62-8P,  
 [4-[2-(5-Carbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]-3-[(ethoxycarbonyl)methoxy]phenoxy]acetic acid ethyl ester 850398-63-9P,  
 [4-[2-(5-Carbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]-3-[(ethoxycarbonyl)methoxy]phenoxy]acetic acid ethyl ester acetate 850398-68-4P,  
 [3-[(Ethoxycarbonyl)methoxy]-4-[2-[5-(N-hydroxycarbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic




acid ethyl ester 850398-69-5P,  
 [2-Ethylsulfanyl-3-hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid ethyl ester  
 850398-79-7P, [2-Ethyl-5-hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid ethyl ester  
 850398-87-7P, [[5-Hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]-2-isopropylphenyl]oxy]acetic acid ethyl ester  
 850398-94-6P, [2-tert-Butyl-5-hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid ethyl ester  
 850399-02-9P,  
 [2-Chloro-5-hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid ethyl ester  
 850399-11-0P, [2-Chloro-3-hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid ethyl ester  
 850399-19-8P, [[3-Hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]-2-methylphenyl]oxy]acetic acid ethyl ester  
 850399-25-6P, [[3-Hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]-2-methylphenyl]oxy]acetic acid benzyl ester  
 850399-32-5P,  
 [2-Ethyl-3-hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid ethyl ester  
 850399-40-5P, [[3-Hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]-2-propylphenyl]oxy]acetic acid ethyl ester  
 850399-47-2P, [[3-Hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]-2-propylphenyl]oxy]acetic acid benzyl ester  
 850399-52-9P,  
 [[4-[2-(5-Carbamimidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]-3-hydroxy-2-propylphenyl]oxy]acetic acid 850399-53-0P,  
 [[4-[2-(5-Carbamimidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]-3-hydroxy-2-propylphenyl]oxy]acetic acid trifluoroacetate 850399-54-1P,  
 [4-Hydroxy-3-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid ethyl ester 850399-59-6P,  
 [3-Hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]-5-methoxyphenoxy]acetic acid ethyl ester 850399-66-5P  
 , [3,5-Dihydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid ethyl ester  
 850399-74-5P, [2-[(Ethoxycarbonyl)methoxy]-3-hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid ethyl ester 850399-80-3P,  
 [2-[(Ethoxycarbonyl)methoxy]-5-hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid ethyl ester  
 850399-88-1P, [4-[2-(5-Carbamimidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]piperazin-1-yl]acetic acid ethyl ester 850399-89-2P,  
 [4-[2-(5-Carbamimidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]piperazin-1-yl]acetic acid ethyl ester acetate 850399-95-0P,  
 [[1-[ (2S) -[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]-3-(4-hydroxyphenyl)propionyl]piperidin-4-yl]oxy]acetic acid ethyl ester  
 850400-00-9P, [[1-[2-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]piperidin-4-yl]oxy]acetic acid ethyl ester  
 850400-06-5P, [[1-[3-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]propionyl]piperidin-4-yl]oxy]acetic acid ethyl ester  
 850400-12-3P, [[1-[2-(5-Carbamimidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]piperidin-4-yl]oxy]acetic acid ethyl ester 850400-13-4P  
 , [[1-[2-(5-Carbamimidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]piperidin-4-yl]oxy]acetic acid ethyl ester acetate 850400-14-5P,  
 [[1-[2-[5-[(tert-Butoxycarbonylamino)(imino)methyl]-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]piperidin-4-yl]oxy]acetic acid ethyl ester

850400-15-6P, [[1-[2-(5-Carbamidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]piperidin-4-yl]oxy]acetic acid hydrochloride  
 850400-19-0P, [3-Ethoxy-4-[2-[5-(N-hydroxycarbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid ethyl ester  
 850400-23-6P, [4-[2-(5-Carbamidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]-3-ethoxyphenoxy]acetic acid ethyl ester 850400-24-7P,  
 [4-[2-(5-Carbamidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]-3-ethoxyphenoxy]acetic acid hydrochloride 850400-26-9P,  
 [4-[2-[5-[(Acetylamino)(imino)methyl]-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]-3-hydroxyphenoxy]acetic acid ethyl ester 850400-28-1P  
 , [[4-[2-(5-Carbamidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]-3-hydroxy-2-propylphenyl]oxy]acetic acid ethyl ester 850400-29-2P,  
 [[4-[2-(5-Carbamidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]-3-hydroxy-2-propylphenyl]oxy]acetic acid ethyl ester acetate 850400-30-5P,  
 [[3-Hydroxy-4-[2-[5-(N-hydroxycarbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]-2-propylphenyl]oxy]acetic acid 850400-31-6P,  
 [3-Allyloxy-4-[2-[5-(N-hydroxycarbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid ethyl ester 850400-35-0P,  
 [4-[2-(5-Carbamidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]acetic acid isobutyl ester 850400-36-1P,  
 [4-[2-(5-Carbamidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]phenoxy]acetic acid 850400-37-2P,  
 [4-[2-(5-Carbamidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]-2-[(isobutoxycarbonyl)methoxy]phenoxy]acetic acid isobutyl ester  
 850400-38-3P, [3-[(Ethoxycarbonyl)methoxy]-4-[2-[5-(N-hydroxycarbamidoyl)-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid 850400-39-4P, [[1-[2-(5-Carbamidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]piperidin-4-yl]oxy]acetic acid  
 850400-41-8P, [4-[2-(5-Carbamidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]-3-ethoxyphenoxy]acetic acid  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of fused bicyclic compds., in particular isoindolones, as fibrinogen receptor antagonists and their use for treating thrombotic diseases)

RN 850396-86-0 CAPLUS

CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, methyl ester (CA INDEX NAME)




RN 850396-87-1 CAPLUS

CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, methyl ester, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 850396-86-0

CMF C20 H19 N3 O5



CM 2


CRN 64-19-7

CMF C2 H4 O2




RN 850396-93-9 CAPLUS

CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, methyl ester (CA INDEX NAME)




RN 850396-94-0 CAPLUS

CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, ethyl ester (CA INDEX NAME)




RN 850396-98-4 CAPLUS

CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, ethyl ester (CA INDEX NAME)




RN 850396-99-5 CAPLUS

CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, 1-methylethyl ester (CA INDEX NAME)




RN 850397-04-5 CAPLUS

CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[imino[(methoxycarbonyl)amino]methyl]-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, 1-methylethyl ester (CA INDEX NAME)




RN 850397-05-6 CAPLUS

CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[imino[(2-methylpropoxy)carbonyl]amino]methyl]-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, 1-methylethyl ester (CA INDEX NAME)




RN 850397-06-7 CAPLUS

CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[imino[(phenylmethoxy)carbonyl]amino]methyl]-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, 1-methylethyl ester (CA INDEX NAME)




RN 850397-07-8 CAPLUS

CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, 1-methylethyl ester (CA INDEX NAME)



RN 850397-08-9 CAPLUS


CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, 2-methylpropyl ester, hydriodide (1:1) (CA INDEX NAME)



● HI


RN 850397-14-7 CAPLUS

CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[imino[(methoxycarbonyl)amino]methyl]-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, 2-methylpropyl ester (CA INDEX NAME)




RN 850397-15-8 CAPLUS

CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[imino[[2-methylpropoxy]carbonyl]amino]methyl]-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, 2-methylpropyl ester (CA INDEX NAME)




RN 850397-16-9 CAPLUS

CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[imino[(phenylmethoxy)carbonyl]amino]methyl]-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, 2-methylpropyl ester (CA INDEX NAME)




RN 850397-17-0 CAPLUS

CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[imino[(methylsulfonyl)amino]methyl]-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, 2-methylpropyl ester (CA INDEX NAME)




RN 850397-18-1 CAPLUS

CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, 2-methylpropyl ester (CA INDEX NAME)



RN 850397-19-2 CAPLUS

CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, phenylmethyl ester (CA INDEX NAME)




RN 850397-20-5 CAPLUS

CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, phenylmethyl ester, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 850397-19-2

CMF C26 H23 N3 O5



CM 2

CRN 64-19-7


CMF C2 H4 O2





RN 850397-27-2 CAPLUS


CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 850397-30-7 CAPLUS

CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[imino[(methoxycarbonyl)amino]methyl]-1-oxo-2H-isoindol-2-yl]acetyl]phenoxyl]-, phenylmethyl ester (CA INDEX NAME)



RN 850397-31-8 CAPLUS


CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[imino[(2-methylpropoxy)carbonyl]amino]methyl]-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, phenylmethyl ester (CA INDEX NAME)




CRN 64-19-7  
CMF C2 H4 O2




RN 850397-41-0 CAPLUS  
CN Acetic acid, 2,2'-[[4-[[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-1,2-phenylene]bis(oxy)]bis-, diethyl ester (9CI)  
(CA INDEX NAME)



RN 850397-42-1 CAPLUS  
CN Acetic acid, 2,2'-[[4-[[1,3-dihydro-5-[imino[[2-methylpropoxy)carbonyl]amino]methyl]-1-oxo-2H-isoindol-2-yl]acetyl]-1,2-phenylene]bis(oxy)]bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 850397-43-2 CAPLUS  
CN Acetic acid, 2,2'-[[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]-1-(hydroxyimino)ethyl]-1,2-phenylene]bis(oxy)]bis-, diethyl ester (9CI) (CA INDEX NAME)



RN 850397-44-3 CAPLUS


CN Acetic acid, 2,2'-[[4-[[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-1,2-phenylene]bis(oxy)]bis-, bis(2-methylpropyl) ester, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 850397-50-1 CAPLUS

CN Acetamide, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-N,N-diethyl- (CA INDEX NAME)




RN 850397-51-2 CAPLUS

CN Acetamide, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-N,N-diethyl-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 850397-50-1

CMF C23 H26 N4 O4



CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 850397-56-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]acetyl]oxy]-, phenylmethyl ester  
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 850397-62-5 CAPLUS  
 CN Butanoic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-4-[[ (phenylmethoxy)carbonyl]amino]-, ethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B


— Ph

RN 850397-63-6 CAPLUS  
 CN Butanoic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-4-[[ (phenylmethoxy)carbonyl]amino]-, ethyl ester, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 850397-62-5  
 CMF C31 H32 N4 O7

PAGE 1-A



PAGE 1-B


— Ph

CM 2  
 CRN 64-19-7  
 CMF C2 H4 O2



RN 850397-71-6 CAPLUS  
 CN Butanoic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-4-[(phenylmethoxy)carbonylamino]-, ethyl ester (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


— CH<sub>2</sub>— Ph

RN 850397-72-7 CAPLUS  
 CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]phenyl]thio]-, methyl ester (CA INDEX NAME)



RN 850397-78-3 CAPLUS

CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-2-chlorophenoxy]-, ethyl ester (CA INDEX NAME)




RN 850397-79-4 CAPLUS

CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-2-chlorophenoxy]-, ethyl ester, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 850397-78-3

CMF C21 H20 Cl N3 O5



CM 2

CRN 64-19-7


CMF C2 H4 O2






RN 850397-85-2 CAPLUS

CN Acetic acid, 2-[2-chloro-4-[2-[1,3-dihydro-5-[imino[(2-methylpropoxy)carbonyl]amino]methyl]-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, ethyl ester (CA INDEX NAME)




RN 850397-86-3 CAPLUS

CN Acetic acid, 2-[2-chloro-4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, ethyl ester (CA INDEX NAME)



RN 850397-87-4 CAPLUS

CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-2-(ethylthio)phenoxy]-, ethyl ester (CA INDEX NAME)



RN 850397-88-5 CAPLUS


CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-2-(ethylthio)phenoxy]-, ethyl ester, acetate (1:1) (CA INDEX NAME)

NAME)

CM 1

CRN 850397-87-4

CMF C23 H25 N3 O5 S



CM 2


CRN 64-19-7

CMF C2 H4 O2




RN 850397-96-5 CAPLUS

CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-2-(ethylthio)phenoxy]-, ethyl ester (CA INDEX NAME)



RN 850397-97-6 CAPLUS


CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-2-(ethylthio)phenoxy]-, ethyl ester (CA INDEX NAME)



RN 850397-98-7 CAPLUS  
 CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-2-(ethylsulfonyl)phenoxy]-, ethyl ester, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 850397-97-6  
 CMF C23 H25 N3 O7 S




CM 2

CRN 64-19-7  
 CMF C2 H4 O2




RN 850398-04-8 CAPLUS  
 CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-2-(ethylsulfonyl)phenoxy]-, ethyl ester (CA INDEX NAME)




RN 850398-05-9 CAPLUS

CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-2,6-bis(ethylthio)phenoxy]-, ethyl ester (CA INDEX NAME)




RN 850398-14-0 CAPLUS

CN Acetic acid, 2-[2-(acetamino)-4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, ethyl ester (CA INDEX NAME)




RN 850398-22-0 CAPLUS

CN Glycine, N-[5-[[1,3-dihydro-5-[imino[(2-methylpropoxy)carbonyl]amino]methyl]-1-oxo-2H-isoindol-2-yl]acetyl]-2-(2-ethoxy-2-oxoethoxy)phenyl]-N-(methylsulfonyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 850398-32-2 CAPLUS

CN Glycine, N-[5-[[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-2-(2-ethoxy-2-oxoethoxy)phenyl]-N-(methylsulfonyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 850398-33-3 CAPLUS

CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-3-hydroxyphenoxy]-, ethyl ester (CA INDEX NAME)




RN 850398-34-4 CAPLUS

CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-3-hydroxyphenoxy]-, ethyl ester, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 850398-33-3

CMF C21 H21 N3 O6



CM 2


CRN 64-19-7

CMF C2 H4 O2



RN 850398-41-3 CAPLUS

CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-3-hydroxyphenoxy]-, ethyl ester (CA INDEX NAME)



RN 850398-42-4 CAPLUS


CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-3-hydroxyphenoxy]-, phenylmethyl ester (CA INDEX NAME)






RN 850398-52-6 CAPLUS

CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isindol-2-yl]acetyl]-3-methoxyphenoxy]-, ethyl ester (CA INDEX NAME)




RN 850398-57-1 CAPLUS

CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isindol-2-yl]acetyl]-3-propoxyphenoxy]-, ethyl ester (CA INDEX NAME)



RN 850398-62-8 CAPLUS

CN Acetic acid, 2,2'-[[4-[[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isindol-2-yl]acetyl]-1,3-phenylene]bis(oxy)]bis-, diethyl ester (9CI) (CA INDEX NAME)






RN 850398-63-9 CAPLUS  
 CN Acetic acid, 2,2'-[[4-[[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-1,3-phenylene]bis(oxy)]bis-, diethyl ester, monoacetate (9CI)  
 (CA INDEX NAME)

CM 1

CRN 850398-62-8  
 CMF C25 H27 N3 O8




CM 2

CRN 64-19-7  
 CMF C2 H4 O2




RN 850398-68-4 CAPLUS  
 CN Acetic acid, 2,2'-[[4-[[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-1,3-phenylene]bis(oxy)]bis-, diethyl ester (9CI)  
 (CA INDEX NAME)




RN 850398-69-5 CAPLUS  
 CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-2-(ethylthio)-3-hydroxyphenoxy]-, ethyl ester (CA

INDEX NAME)




RN 850398-79-7 CAPLUS

CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-2-ethyl-5-hydroxyphenoxy]-, ethyl ester (CA INDEX NAME)




RN 850398-87-7 CAPLUS

CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-5-hydroxy-2-(1-methylethyl)phenoxy]-, ethyl ester (CA INDEX NAME)




RN 850398-94-6 CAPLUS


CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-2-(1,1-dimethylethyl)-5-hydroxyphenoxy]-, ethyl ester (CA INDEX NAME)




RN 850399-02-9 CAPLUS  
 CN Acetic acid, 2-[2-chloro-4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-5-hydroxyphenoxy]-, ethyl ester (CA INDEX NAME)




RN 850399-11-0 CAPLUS  
 CN Acetic acid, 2-[2-chloro-4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-3-hydroxyphenoxy]-, ethyl ester (CA INDEX NAME)




RN 850399-19-8 CAPLUS  
 CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-3-hydroxy-2-methylphenoxy]-, ethyl ester (CA INDEX NAME)




RN 850399-25-6 CAPLUS  
 CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-3-hydroxy-2-methylphenoxy]-, phenylmethyl ester (CA INDEX NAME)




RN 850399-32-5 CAPLUS  
 CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-2-ethyl-3-hydroxyphenoxy]-, ethyl ester (CA INDEX NAME)




RN 850399-40-5 CAPLUS  
 CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-3-hydroxy-2-propylphenoxy]-, ethyl ester (CA INDEX NAME)



RN 850399-47-2 CAPLUS  
 CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-3-hydroxy-2-propylphenoxy]-, phenylmethyl ester (CA INDEX NAME)



RN 850399-52-9 CAPLUS  
 CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-3-hydroxy-2-propylphenoxy]- (CA INDEX NAME)




RN 850399-53-0 CAPLUS  
 CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-3-hydroxy-2-propylphenoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 850399-52-9

CMF C22 H23 N3 O6



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 850399-54-1 CAPLUS

CN Acetic acid, 2-[3-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-4-hydroxyphenoxy]-, ethyl ester (CA INDEX NAME)




RN 850399-59-6 CAPLUS

CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-3-hydroxy-5-methoxyphenoxy]-, ethyl ester (CA INDEX NAME)




RN 850399-66-5 CAPLUS

CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-3,5-dihydroxyphenoxy]-, ethyl ester (CA INDEX NAME)




RN 850399-74-5 CAPLUS

CN Acetic acid, 2,2'-[[4-[[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-3-hydroxy-1,2-phenylene]bis(oxy)]bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 850399-80-3 CAPLUS

CN Acetic acid, 2,2'-[[4-[[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-5-hydroxy-1,2-phenylene]bis(oxy)]bis-, diethyl ester (9CI) (CA INDEX NAME)



RN 850399-88-1 CAPLUS


CN 1-Piperazineacetic acid, 4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-, ethyl ester (CA INDEX NAME)



RN 850399-89-2 CAPLUS  
 CN 1-Piperazineacetic acid, 4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-, ethyl ester, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 850399-88-1  
 CMF C19 H25 N5 O4



CM 2


CRN 64-19-7  
 CMF C2 H4 O2



RN 850399-95-0 CAPLUS  
 CN Acetic acid, 2-[[1-[(2S)-2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]-3-(4-hydroxyphenyl)-1-oxopropyl]-4-piperidinyl]oxy]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.






RN 850400-00-9 CAPLUS

CN Acetic acid, 2-[[1-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-4-piperidinyl]oxy]-, ethyl ester (CA INDEX NAME)




RN 850400-06-5 CAPLUS

CN Acetic acid, 2-[[1-[3-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]-1-oxopropyl]-4-piperidinyl]oxy]-, ethyl ester (CA INDEX NAME)



RN 850400-12-3 CAPLUS


CN Acetic acid, 2-[[1-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-4-piperidinyl]oxy]-, ethyl ester (CA INDEX NAME)



RN 850400-13-4 CAPLUS  
 CN Acetic acid, 2-[[1-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-4-piperidinyl]oxy]-, ethyl ester, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 850400-12-3  
 CMF C20 H26 N4 O5




CM 2

CRN 64-19-7  
 CMF C2 H4 O2




RN 850400-14-5 CAPLUS  
 CN Acetic acid, 2-[[1-[2-[5-[[[(1,1-dimethylethoxy)carbonyl]amino]iminomethyl]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-4-piperidinyl]oxy]-, ethyl ester (CA INDEX NAME)



RN 850400-15-6 CAPLUS


CN Acetic acid, 2-[[1-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-4-piperidinyloxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 850400-19-0 CAPLUS

CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-3-ethoxyphenoxy]-, ethyl ester (CA INDEX NAME)




RN 850400-23-6 CAPLUS

CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-3-ethoxyphenoxy]-, ethyl ester (CA INDEX NAME)



RN 850400-24-7 CAPLUS


CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-3-ethoxyphenoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 850400-26-9 CAPLUS

CN Acetic acid, 2-[4-[2-[5-[(acetylamino)iminomethyl]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-3-hydroxyphenoxy]-, ethyl ester (CA INDEX NAME)



RN 850400-28-1 CAPLUS


CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-3-hydroxy-2-propylphenoxy]-, ethyl ester (CA INDEX NAME)



RN 850400-29-2 CAPLUS  
 CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-3-hydroxy-2-propylphenoxy]-, ethyl ester, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 850400-28-1  
 CMF C24 H27 N3 O6




CM 2


CRN 64-19-7  
 CMF C2 H4 O2




RN 850400-30-5 CAPLUS  
 CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-3-hydroxy-2-propylphenoxy]- (CA INDEX NAME)




RN 850400-31-6 CAPLUS  
 CN Acetic acid, 2-[4-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-3-(2-propen-1-yloxy)phenoxy]-, ethyl ester (CA INDEX NAME)




RN 850400-35-0 CAPLUS  
 CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, 2-methylpropyl ester (CA INDEX NAME)




RN 850400-36-1 CAPLUS  
 CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]- (CA INDEX NAME)




RN 850400-37-2 CAPLUS  
 CN Acetic acid, 2,2'-[[4-[[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isindol-2-yl]acetyl]-1,2-phenylene]bis(oxy)]bis-, bis(2-methylpropyl) ester (9CI)  
 (CA INDEX NAME)



RN 850400-38-3 CAPLUS  
 CN Acetic acid, 2-[5-(carboxymethoxy)-2-[2-[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isindol-2-yl]acetyl]phenoxy]-, 1-ethyl ester (CA INDEX NAME)




RN 850400-39-4 CAPLUS  
 CN Acetic acid, 2-[[1-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isindol-2-yl]acetyl]-4-piperidinyl]oxy]- (CA INDEX NAME)



RN 850400-41-8 CAPLUS


CN Acetic acid, 2-[4-[2-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-3-ethoxyphenoxy]- (CA INDEX NAME)



IT 850397-28-3P, [4-[2-[5-[(tert-Butoxycarbonylamino)(imino)methyl]-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid ethyl ester  
 850397-29-4P, [4-[2-[5-[(tert-Butoxycarbonylamino)(imino)methyl]-1-oxo-1,3-dihydroisoindol-2-yl]acetyl]phenoxy]acetic acid  
 850398-31-1P, [4-[2-[5-(Carbamimidoyl-1-oxo-1,3-dihydroisoindol-2-yl)acetyl]-2-[(ethoxycarbonyl)methyl](methylsulfonyl)amino]phenoxy]acetic acid ethyl ester acetate  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of fused bicyclic compds., in particular isoindolones, as fibrinogen receptor antagonists and their use for treating thrombotic diseases)

RN 850397-28-3 CAPLUS


CN Acetic acid, 2-[4-[2-[5-[[[(1,1-dimethylethoxy)carbonyl]amino]iminomethyl]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]-, ethyl ester (CA INDEX NAME)



RN 850397-29-4 CAPLUS



CN Acetic acid, 2-[4-[2-[5-[[[(1,1-dimethylethoxy)carbonyl]amino]iminomethyl]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]phenoxy]- (CA INDEX NAME)




RN 850398-31-1 CAPLUS

CN Glycine, N-[5-[5-(aminoiminomethyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]acetyl]-2-(2-ethoxy-2-oxoethoxy)phenyl]-N-(methylsulfonyl)-, ethyl ester, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 850398-30-0

CMF C26 H30 N4 O9 S



CM 2

CRN 64-19-7

CMF C2 H4 O2



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log h  
COST IN U.S. DOLLARS

SINCE FILE TOTAL

10574982.trn

FULL ESTIMATED COST	ENTRY 6.64	SESSION 384.06
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.82	-1.64

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 17:35:16 ON 16 FEB 2009